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Abstract
Objective The objective of this randomized, double-blind,
placebo-controlled study was to evaluate the efficacy and
safety of SHP465 mixed amphetamine salts (MAS) in adults
with attention-deficit/hyperactivity disorder (ADHD).
Methods Eligible adults [aged 18–55 years; meeting the
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition ADHD criteria; baseline ADHD Rating Scale
with Adult Prompts (ADHD-RS-AP) total scoresC28] were
randomized 1:1:1 to placebo or forced-dose SHP465 MAS
(12.5 or 37.5 mg/day) for 4 weeks. The ADHD-RS-AP total
score change from baseline toweek 4 (primary endpoint) and
Clinical Global Impressions-Improvement score at week 4
(key secondary endpoint) were assessed using linear mixed-
effects models for repeated measures. Other efficacy end-
points were changes from baseline to week 4 on the ADHD-
RS-AP hyperactivity/impulsivity and inattentiveness sub-
scales and the percentage of participants categorized as
improved on the dichotomized Clinical Global Impressions-
Improvement. Safety and tolerability assessments were
treatment-emergent adverse events, vital sign and weight
changes, Columbia-Suicide Severity Rating Scale respon-
ses, and electrocardiogram results.
Results Of 369 screened participants, 275 were randomized
(placebo, n = 91; 12.5 mg/day of SHP465 MAS, n = 92;
37.5 mg/day of SHP465 MAS, n = 92) and 236 completed
the study (placebo, n = 80; 12.5 mg/day of SHP465 MAS,
n = 80; 37.5 mg/day of SHP465 MAS, n = 76). Least-
squares mean (95% confidence interval) treatment differ-
ences at week 4 significantly favored SHP465 MAS over
placebo for the ADHD-RS-AP total score change from
baseline [12.5 mg/day: -8.1 (-11.7, -4.4), effect
size = 0.67; 37.5 mg/day: -13.4 (-17.1, -9.7), effect
size = 1.11; both p\ 0.001] and Clinical Global Impres-
sions-Improvement score [12.5 mg/day:-0.8 (-1.1,-0.4),
effect size = 0.68; 37.5 mg/day: -1.2 (-1.6, -0.9), effect
size = 1.11; both p\ 0.001]. Treatment differences for the
change from baseline at week 4 favored 12.5 and
37.5 mg/day of SHP465MAS, respectively, over placebo on
the ADHD-RS-AP hyperactivity/impulsivity (both nominal
p\ 0.001; effect size = 0.56 and 0.91) and inattentiveness
(both nominal p\ 0.001; effect size = 0.70 and 1.19) sub-
scales. At the final on-treatment assessment, the percentage
of participants categorized as improved on Clinical Global
Impressions-Improvement was higher with both SHP465
MAS doses than with placebo (both nominal p\ 0.001).
Treatment-emergent adverse events reported ([5%) with
SHP465 MAS were decreased appetite, dry mouth, insom-
nia, headache, anxiety, initial insomnia, irritability, and
bruxism. Severe treatment-emergent adverse events and
treatment-emergent adverse events leading to discontinua-
tion, respectively, were reported by 8 and 12 participants
(placebo, n = 2 and 0; 12.5 mg/day SHP465 MAS, n = 1
and 7; 37.5 mg/day SHP465MAS, n = 5 and 5). At the final
on-treatment assessment, mean ± standard deviation
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increases from baseline were observed with 12.5 and
37.5 mg/day of SHP465 MAS for pulse (3.3 ± 10.52 and
7.1 ± 11.48 bpm) and blood pressure (systolic 0.2 ± 7.24
and 1.7 ± 9.99 mmHg; diastolic 1.0 ± 7.46 and
2.8 ± 7.90 mmHg) and decreases were observed for weight
(-0.97 ± 1.523 and -1.65 ± 2.333 kg), body mass
index (-0.33 ± 0.519 and -0.56 ± 0.777 kg/m2), and
Fridericia corrected QT interval (-3.0 ± 10.72 and
-1.6 ± 13.70 ms). No participant in any treatment group
had a positive response for on-study Columbia-Suicide
Severity Rating Scale assessments.
Conclusions SHP465 MAS was superior to placebo in
reducing ADHD symptoms, with a safety profile consistent
with other long-acting stimulants.
ClinicalTrials.gov Registry Number: NCT02604407.
Key Points
In adults with attention-deficit/hyperactivity disorder
(ADHD), 12.5 and 37.5 mg/day of SHP465 mixed
amphetamine salts (MAS) produced significantly
greater reductions in ADHD symptoms, as measured
by the total score on the ADHD Rating Scale with
Adult Prompts, than did placebo after 4 weeks of
treatment.
At the end of the study, 37.5 mg/day of SHP465
MAS vs. placebo demonstrated a robust effect size of
1.11 for the primary efficacy endpoint (ADHD
Rating Scale with Adult Prompts total score) and the
key secondary efficacy endpoint (Clinical Global
Impressions-Improvement score), with the effects of
12.5 mg/day of SHP465 MAS being numerically
lower than 37.5 mg/day of SHP465 MAS.
The overall safety and tolerability profile of SHP465
MAS, in terms of treatment-emergent adverse events
and vital sign changes, aligned with the known
effects of other long-acting amphetamine
formulations.
Taken together with previous findings, SHP465
MAS is a viable treatment for adults with ADHD.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) presents
clinically in children and adolescents, and it may persist in
a sizeable portion of adults [1–4]. When pharmacotherapy
for adults diagnosed with ADHD is pursued, the initial
treatment choice is generally a psychostimulant [5, 6],
which is in accordance with US practice recommendations
for children and adolescents with ADHD [7]. Although
reviews suggest that currently available long-acting psy-
chostimulants have estimated durations of effect ranging
from 8 to 14 h [8–10], some physicians may augment their
patients’ long-acting psychostimulant with another ADHD
medication later in the day because the long-acting psy-
chostimulant alone does not provide all-day coverage. In a
clinical program practice survey of adults being treated for
ADHD, approximately 40% of patients were receiving a
combination of short- and long-acting psychostimulants
[11].
SHP465 mixed amphetamine salts (SHP465 MAS) is a
novel, once-daily, extended-release, single-entity MAS
product for oral administration approved in USA for the
treatment of ADHD in patients aged 13 years and older.
SHP465 MAS was designed with the goal of providing a
medication with the potential to reduce the ADHD symp-
toms throughout the day and into the evening in individuals
who require such coverage. It contains equal amounts (by
weight) of four salts: dextroamphetamine sulfate and
amphetamine sulfate, dextroamphetamine saccharate and
amphetamine aspartate monohydrate. This results in a 3:1
mixture of dextro- to levoamphetamine base equivalent.
Each capsule contains three types of drug-releasing beads,
an immediate-release bead and two different types of
delayed-release beads. The first delayed-release bead
releases amphetamine at pH 5.5 and the other delayed-
release bead releases amphetamine at pH 7.0. In a phase I
study, the pharmacokinetic profile of 37.5 mg/day of
SHP465 MAS was similar to that of 25 mg/day of exten-
ded-release MAS (MAS XR) in the morning supplemented
8 h later by 12.5 mg/day of immediate-release MAS [12],
suggesting it may be a viable once-daily treatment for
ADHD.
The efficacy, tolerability, and safety of SHP465 MAS in
adults with ADHD have been examined in several phase III
studies [13–15]. In a forced-dose study, the efficacy, tol-
erability, and safety of 25, 50, and 75 mg/day of SHP465
MAS were examined [15]. In that study, all SHP465 MAS
doses produced significantly greater reductions in ADHD
symptoms than did placebo, but a clear and clinically
meaningful, dose-dependent response between low and
high doses of SHP465 MAS was not established [15]. In
another study, the efficacy, tolerability, and safety of dose-
optimized SHP465 MAS (12.5–75 mg/day) were evalu-
ated; however, owing to the use of dose optimization,
relationships among the individual SHP465 MAS doses
used in that study (12.5, 25, 37.5, 50, 62.5, and 75 mg/day)
were not examined [13]. This forced-dose study specifi-
cally evaluated the efficacy, tolerability, and safety of 12.5
and 37.5 mg/day of SHP465 MAS, with the 12.5-mg/day
dose being evaluated to further elucidate the lower end of
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the dose response relationship of SHP465 MAS. The
objectives of this study were to evaluate the efficacy,
safety, and tolerability of SHP465 MAS vs. placebo in the
treatment of adults with ADHD.
2 Materials and Methods
This phase III, randomized, double-blind, parallel-group,
placebo-controlled, forced-dose study (ClinicalTrials.gov
registry: NCT02604407) was conducted at 43 US sites
[participants randomized/enrolled across sites (median 6;
range 1–19); no more than 7% of participants enrolled from
each study site] in accordance with the International Con-
ference on Harmonisation and Good Clinical Practice and
the principles of the Declaration of Helsinki. The study
protocol, final approved informed consent document, and
all supporting information were submitted to and approved
by a central institutional review board (Copernicus Group
Independent Review Board, Durham, NC, USA) and by the
US Food and Drug Administration as appropriate before
study initiation. All participants provided written informed
consent before taking part in study procedures.
2.1 Participants
Men and non-pregnant women (aged 18–55 years) meeting
the Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition criteria for a primary ADHD diagnosis and
having ADHD Rating Scale with Adult Prompts (ADHD-
RS-AP) total scores C28 at baseline were enrolled. Eligible
participants had satisfactory medical assessments with no
clinically significant abnormalities and they were either not
currently on ADHD therapy or they reported that they were
not completely satisfied with any aspect, including issues
related to efficacy and tolerability, of their current ADHD
therapy.
Participants were excluded if they had a comorbid
psychiatric diagnosis that was controlled with prohibited
medications or uncontrolled and associated with significant
symptoms that contraindicated SHP465 MAS treatment or
could confound study assessments. Participants were also
ineligible if they were considered a suicide risk, had pre-
viously made a suicide attempt, or were currently demon-
strating active suicidal ideation (those with intermittent
passive suicidal ideation could be included based on
investigator judgment). Other exclusion criteria included a
body mass index (BMI) \18.5 kg/m2 (underweight) or
C40 kg/m2 (very severely obese) at screening; a history of
moderate-to-severe hypertension, average sitting systolic
blood pressure (SBP) [139 mmHg, or average sitting
diastolic blood pressure (DBP)[89 mmHg; use of com-
bination antihypertensive medications (participants with
well-controlled mild hypertension on a single antihyper-
tensive agent could participate); a known history of
symptomatic cardiovascular issues or serious cardiac
problems; a known family history of sudden cardiac death
or ventricular arrhythmia; a clinically significant electro-
cardiogram; a documented allergy, a hypersensitivity, or an
intolerance to amphetamine or any excipient in SHP465
MAS; a failure to respond to an adequate course of
amphetamine therapy (to ensure that response to treatment
is not artificially reduced by the inclusion of non-respon-
ders); a history of suspected substance abuse or dependence
disorder (excluding nicotine) based on the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition cri-
teria; a lifetime history of amphetamine, cocaine, or other
stimulant abuse and/or dependence; and participation in a
clinical study within 30 days before screening.
Prohibited medications were psychostimulants and
amphetamine-like agents, centrally or peripherally acting
antihistamines (non-sedating antihistamines were permit-
ted), investigational compounds, clonidine and guanfacine,
and herbal preparations. Additional medications that were
prohibited because they indicated the potential presence of
an exclusionary diagnosis were combination anti-hyper-
tensives (use of a single antihypertensive was permitted if
the same dose had been used for at least 3 months before
screening), sedatives, anxiolytics, antipsychotics, mono-
amine oxidase inhibitors, antidepressants, selective nora-
drenaline reuptake inhibitors, and noradrenaline reuptake
inhibitors. Participants requiring or anticipating the need to
take medications with central nervous system effects or
who were taking monoamine oxidase inhibitors were
excluded (stable bronchodilator inhaler use was not
exclusionary).
2.2 Treatment
The study included four periods (screening and washout,
forced-dose titration, dose maintenance, safety follow-up)
(Fig. 1). After the screening and washout period
(7–30 days depending on use of prohibited medications at
screening), participants were randomized 1:1:1 to 1 of three
treatment groups for 4 weeks: 12.5 mg/day of SHP465
MAS, 37.5 mg/day of SHP465 MAS, or matching placebo.
Participants were instructed to take their treatment in the
morning at approximately 7:00 a.m. (±2 h).
Treatment assignments were made by an interactive web
response system. Within each study site, unique participant
numbers were assigned according to the sequence of pre-
sentation for study participation after determination of
study eligibility. The packaging of the study drug and the
appearance of each treatment were identical across treat-
ment arms. The investigators, the investigators’ staff, and
the participants were blinded to the treatment assignment.
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During the forced-dose titration period (weeks 1 and 2),
participants randomized to SHP465 MAS initiated treat-
ment at 12.5 mg/day during week 1. Participants random-
ized to 12.5 mg/day of SHP465 MAS maintained this dose
during week 2. In participants randomized to 37.5 mg/day
of SHP465 MAS, the dose was titrated to 25 mg/day dur-
ing week 2 and to 37.5 mg/day during week 3. Throughout
the forced-dose titration period, dose escalation was dic-
tated by treatment group, and dose changes were not
allowed. Participants were discontinued if they experienced
unacceptable tolerability. During dose maintenance (weeks
3 and 4), participants were maintained at their randomized
dose. The follow-up period was 7 (?2) days from the last
dose of the study drug. At the end of the follow-up period,
information related to the occurrence of adverse events
(AEs) and concomitant treatments was requested via a
telephone call.
2.3 Efficacy Endpoints
The primary efficacy endpoint was ADHD-RS-AP total
score change from baseline to week 4 in the full analysis
set, which included all screened participants assigned a
randomization number who took one or more study drug
doses and who had one or more post-baseline on-treatment
primary efficacy assessments. The ADHD-RS-IV [16] was
developed to measure behavior in children with ADHD. In
this study, the ADHD-RS-AP, which consists of 18 items
reflecting current ADHD symptoms based on the Diag-
nostic and Statistical Manual of Mental Disorders, Fifth
Edition criteria, was used. The adult prompts create a semi-
structured measurement allowing clinicians to probe the
extent, frequency, breadth, severity, and consequences of
adult ADHD [17]. Items are scored on 4-point scales [0 (no
symptoms) to 3 (severe symptoms)]; total score ranges
from 0 to 54. The scale is divided into two subscales,
hyperactivity/impulsivity and inattentiveness, consisting of
nine items each. The ADHD-RS-AP was completed at each
visit by an experienced clinician who was certified on the
scale.
The key secondary efficacy endpoint was Clinical Glo-
bal Impressions-Improvement (CGI-I) score at week 4. The
CGI-I measures improvement in global symptom severity
on a 7-point scale [1 (very much improved) to 7 (very
much worse)] [18], with improvement measured against
baseline CGI-Severity (CGI-S) scores. The CGI-I and
CGI-S were completed by clinicians experienced in eval-
uating adult ADHD. Other secondary efficacy assessments
included changes from baseline at week 4 on the subscales
of ADHD-RS-AP and global functioning improvement
based on the dichotomized CGI-I.
2.4 Safety Endpoints
Safety and tolerability assessments included treatment-
emergent AEs (TEAEs), vital sign and weight changes,
Columbia-Suicide Severity Rating Scale (C-SSRS)
responses, and electrocardiogram results. All AEs were
collected from the time of informed consent until the end
of follow-up. Treatment-emergent AEs were defined as
AEs occurring during double-blind treatment that (1) had
start dates on or after the first study drug dose or (2) had
start dates before the first study drug dose but that
increased in severity on or after the date of the first study
drug dose. Vital signs and weight were assessed at
screening, baseline, and all visits through week 4/final on-
treatment assessment, as were responses on the C-SSRS,
which is a semi-structured interview that assesses suicidal
ideation and behavior and non-suicidal self-injurious
behavior [19]. Vital signs were assessed after approxi-
mately 3 min of rest with participants in a seated position
and consisted of three assessments taken at approximately
2-min intervals. The 12-lead electrocardiogram was
assessed at screening, baseline, week 2, and week 4/final
Fig. 1 Study design. ET early termination, MAS mixed amphetamine salts, PBO placebo, V visit
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on-treatment assessment after 3 min of rest; the baseline
assessment consisted of three recordings taken at 3-min
intervals.
2.5 Data Presentation and Statistics
Sample size was estimated for the primary efficacy com-
parison using nQuery Advisor 7.0 (Statistical Solutions
Ltd, Cork, Ireland). To detect a treatment difference of 7.0
[assumed common standard deviation (SD), 11.6] for the
ADHD-RS-AP total score change from baseline, 60 par-
ticipants per group were needed to provide 90% power for
a two-sided t test (a = 0.05). Therefore, a total of 180
participants (60 for each SHP465 MAS dose and 60 for
placebo) needed to be randomized. With an expected post-
randomization dropout rate of 30%, the randomization
target was set at 258 participants. The estimated treatment
difference and SD corresponded to an effect size (ES) of
0.6 and was based on a previously completed phase III
study of SHP465 MAS [15].
All statistical analyses of efficacy were conducted in the
full analysis set. The primary efficacy endpoint (ADHD-
RS-AP total score change from baseline at week 4) was
analyzed using a linear mixed-effects model for repeated
measures, with treatment group, visit, and the interaction of
treatment group with the visit as factors; baseline ADHD-
RS-AP total score as a covariate; and the interaction of
baseline ADHD-RS-AP total score with the visit adjusted
in the model. The null hypothesis was that there was no
difference in the mean change from baseline at week 4 in
the ADHD-RS-AP total score between each SHP465 MAS
treatment group and the placebo group. The primary con-
trast was each dose of SHP465 MAS vs. placebo. To
compare SHP465 MAS with placebo, the least-squares
(LS) mean treatment difference for the change from base-
line at week 4 and the corresponding 95% confidence
interval and p value were calculated; ES (the LS mean
difference divided by the square root of the variance esti-
mate at week 4) was also calculated. Two sensitivity
analysis models were used to examine the robustness of the
primary analysis. These models assumed different missing
not at random mechanisms and were within the pattern-
mixture model framework.
The key secondary efficacy endpoint, CGI-I score at
week 4, was analyzed using the same analysis methods
described for the primary efficacy endpoint. Other assess-
ments of efficacy were changes from baseline at week 4 on
the ADHD-RS-AP subscales and dichotomized improve-
ment on the CGI-I. Changes in ADHD-RS-AP subscales
from baseline to week 4 were analyzed using the same
mixed-effects model for repeated measures described for
the primary efficacy endpoint. The dichotomized CGI-I
analysis examined the percentage of participants who
improved on the CGI-I at the final on-treatment assess-
ment, with ‘‘improved’’ categorized as scores of 1 (very
much improved) or 2 (much improved) and ‘‘not
improved’’ categorized as scores of 3 (minimally
improved) through 7 (very much worse). The percentage of
improved participants for each SHP465 MAS dose vs.
placebo was analyzed with a Cochran–Mantel–Haenszel
test stratified by baseline CGI-S.
To preserve study-wide type I error at a two-sided
a = 0.05 across the primary and key secondary efficacy
assessments, a fixed-sequence test procedure was applied.
In this procedure, each test was evaluated at a two-sided
significance level of 0.05 and a later test could only be
reported as significant if all earlier tests were significant.
The order of assessment was as follows: 37.5 mg/day of
SHP465 MAS vs. placebo for the ADHD-RS-AP total
score change from baseline at week 4; 12.5 mg/day of
SHP465 MAS vs. placebo for the ADHD-RS-AP total
score change from baseline at week 4; 37.5 mg/day of
SHP465 MAS vs. placebo for the CGI-I score at week 4;
and 12.5 mg/day of SHP465 MAS vs. placebo for the CGI-
I score at week 4. The study was not powered for the
assessment of change from baseline at week 4 in ADHD-
RS-AP subscale scores or for dichotomized improvement
on the CGI-I at the final on-treatment assessment, and these
endpoints were not included in the testing strategy.
Therefore, all reported p values for these endpoints are
nominal (unadjusted) and reported for descriptive purposes
only. Safety and tolerability endpoints were assessed in the
safety analysis set (all screened participants assigned a
randomization number who took one or more study drug
doses) and are reported using descriptive statistics.
3 Results
3.1 Participant Disposition and Demographics
Participant disposition is summarized in Fig. 2. Of 369
screened participants, 275 were randomized (placebo,
n = 91; 12.5 mg/day of SHP465 MAS, n = 92;
37.5 mg/day of SHP465 MAS, n = 92). A total of 271 and
263 participants, respectively, were included in the safety
analysis set (placebo, n = 89; 12.5 mg/day of SHP465
MAS, n = 92; 37.5 mg/day of SHP465 MAS, n = 90) and
full analysis set (placebo, n = 86; 12.5 mg/day of SHP465
MAS, n = 89; 37.5 mg/day of SHP465 MAS, n = 88).
Demographic and clinical characteristics are summa-
rized in Table 1. Participants were almost evenly divided
across treatment arms. Overall, slightly more participants
were men [150/271 (55.4%)] and a majority were white
[81.5% (221/271)]. Mean age ranged from 32.4 years
(37.5 mg/day of SHP465 MAS) to 34.5 years (placebo).
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Mean baseline ADHD-RS-AP total score ranged from 39.9
(37.5 mg/day of SHP465 MAS) to 40.4 (placebo); 80.8%
(219/271) of participants were categorized as having the
combined ADHD subtype.
3.2 Prior and Concomitant ADHD Medication Use
Prior ADHD medication was used in 71.9% (64/89), 62.0%
(57/92), and 68.9% (62/90) of participants, respectively, in
the placebo, 12.5-mg/day SHP465 MAS, and 37.5-mg/day
SHP465 MAS treatment groups. The most frequently used
ADHD medications (reported by C5% of participants in
any treatment group) were immediate-release MAS [pla-
cebo, 44.9% (40/89); 12.5 mg/day of SHP465 MAS, 38.0%
(35/92); 37.5 mg/day of SHP465 MAS, 32.2% (29/90)],
methylphenidate [33.7% (30/89); 29.3% (27/92); 37.8%
(34/90)], lisdexamfetamine [22.5% (20/89); 18.5% (17/92);
20.0% (18/90)], atomoxetine [5.6% (5/89); 9.8% (9/92);
10.0% (9/90)], and bupropion [2.2% (2/89); 4.3% (4/92);
5.6% (5/90)].
Concomitant medications were used by 64.0% (57/89),
52.2% (48/92), and 60.0% (54/90) of participants, respec-
tively, in the placebo, 12.5-mg/day of SHP465 MAS, and
37.5-mg/day SHP465 MAS treatment groups. The most
frequently reported concomitant medications (reported by
C5% of participants in any treatment group) were ibuprofen
[placebo, 15.7% (14/89); 12.5 mg/day of SHP465 MAS,
14.1% (13/92); 37.5 mg/day of SHP465 MAS, 15.6%
(14/90)], multivitamins [9.0% (8/89); 6.5% (6/92); 11.1%
(10/90)], acetaminophen [7.9% (7/89); 7.6% (7/92); 5.6%
(5/90)], and loratadine [5.6% (5/89); 1.1% (1/92); 3.3%
(3/90)]. Immediate-release MAS [placebo, 2.2% (2/89);
12.5 mg/day of SHP465 MAS, 3.3% (3/92); 37.5 mg/day of
SHP465 MAS, 5.6% (5/90)] and lisdexamfetamine [pla-
cebo, 3.4% (3/89); 12.5 mg/day of SHP465 MAS, 1.1%
(1/92); 37.5 mg/day of SHP465 MAS, 1.1% (1/90)] were
Fig. 2 Participant disposition. MAS mixed amphetamine salts
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the only concomitant ADHD medications used by C2% of
participants in any treatment group. These instances were
defined as protocol deviations or violations, and the num-
bers of participants taking these medications was low and
comparable across treatment groups.
3.3 Efficacy
3.3.1 Primary Endpoint
Mean ADHD-RS-AP total scores decreased with all study
treatments (Fig. 3a). Inferential analysis indicated that LS
mean ± standard error of the mean changes from baseline
in ADHD-RS-AP total score at week 4 were -18.5 ± 1.31
and -23.8 ± 1.34 in the 12.5- and 37.5-mg/day SHP465
MAS treatment groups, respectively; these reductions from
baseline in ADHD-RS-AP total scores were statistically
significantly greater than with placebo (-10.4 ± 1.33;
both p\ 0.001; Table 2). For the 12.5- and 37.5-mg/day
SHP465 MAS treatment groups, respectively, ES was 0.67
and 1.11 (Table 2). Sensitivity analyses supported findings
of the primary efficacy analysis (see Electronic Supple-
mentary Material).
3.3.2 Secondary Endpoints
Mean CGI-I score decreased during the study in all treat-
ment groups (Fig. 3b). Least-squares mean ± standard
Table 1 Participant demographic and baseline clinical characteristics, safety analysis set
Placebo (n = 89) SHP465 MAS
12.5 mg/day (n = 92) 37.5 mg/day (n = 90)
Mean ± SD age, years 34.5 ± 10.77 33.0 ± 10.40 32.4 ± 10.02
Sex, n (%)
Male 42 (47.2) 57 (62.0) 51 (56.7)
Female 47 (52.8) 35 (38.0) 39 (43.3)
Race, n (%)
White 74 (83.1) 76 (82.6) 71 (78.9)
Black/African American 6 (6.7) 10 (10.9) 7 (7.8)
Native Hawaiian/Pacific Islander 1 (1.1) 1 (1.1) 1 (1.1)
Asian 2 (2.2) 1 (1.1) 4 (4.4)
American Indian/Alaska Native 2 (2.2) 0 (0) 1 (1.1)
Multiple 4 (4.5) 4 (4.3) 4 (4.4)
Other 0 (0) 0 (0) 2 (2.2)
Mean ± SD weight, kg 82.82 ± 17.314 84.04 ± 18.733 83.94 ± 20.942
Mean ± SD body mass index, kg/m2 28.11 ± 5.356 27.93 ± 5.179 27.78 ± 5.586
Mean ± SD ADHD-RS-AP score
Total 40.4 ± 6.45 40.0 ± 6.36 39.9 ± 7.00
Inattentivenessa 22.5 ± 3.36 22.5 ± 3.06 22.8 ± 3.39
Hyperactivity/impulsivitya 18.0 ± 5.13 17.3 ± 5.43 17.1 ± 5.54
ADHD subtype, n (%)
Inattentive 16 (18.0) 15 (16.3) 19 (21.1)
Hyperactive/impulsive 1 (1.1) 1 (1.1) 0 (0)
Combined 72 (80.9) 76 (82.6) 71 (78.9)
Mean ± SD age of ADHD onset, years 6.1 ± 1.69 6.3 ± 1.47 6.5 ± 1.70
Mean ± SD time since ADHD diagnosis, years 10.4 ± 11.28 9.9 ± 10.99 10.5 ± 11.41
CGI-S, n (%)
Moderately ill 37 (41.6) 37 (40.2) 42 (46.7)
Markedly ill 43 (48.3) 44 (47.8) 40 (44.4)
Severely ill 8 (9.0) 10 (10.9) 8 (8.9)
Among the most extremely ill 1 (1.1) 1 (1.1) 0 (0)
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-AP ADHD Rating Scale with Adult Prompts, CGI-S Clinical Global Impressions-
Severity, MAS mixed amphetamine salts, SD standard deviation
a Based on the full analysis set (placebo, n = 86; 12.5 mg/day of SHP465 MAS, n = 89; 37.5 mg/day of SHP465 MAS, n = 88)
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error of the mean CGI-I scores at week 4 (the key sec-
ondary endpoint) were 2.4 ± 0.12 and 1.9 ± 0.13 in the
12.5- and 37.5-mg/day SHP465 MAS treatment groups,
respectively; these scores were statistically significantly
lower than placebo (3.1 ± 0.12; both p\ 0.001; Table 2).
For 12.5- and 37.5-mg/day SHP465 MAS treatment
groups, respectively, ES was 0.68 and 1.11 (Table 2).
Other secondary efficacy results are summarized in
Table 2. The LS mean treatment difference for the change
from baseline at week 4 on the ADHD-RS-AP hyperac-
tivity/impulsivity subscale favored 12.5 and 37.5 mg/day
of SHP465 MAS over placebo (both nominal p\ 0.001;
ES = 0.56 and 0.91, respectively; Table 2). Similarly, LS
mean treatment differences for the change from baseline at
week 4 on the ADHD-RS-AP inattentiveness subscale
favored 12.5 and 37.5 mg/day of SHP465 MAS over pla-
cebo (both nominal p\ 0.001; ES = 0.70 and 1.19,
respectively; Table 2). At the final on-treatment assess-
ment, the percentage of participants categorized as
improved on CGI-I was higher with 12.5 mg/day of
SHP465 MAS [55.1% (49/89)] and 37.5 mg/day of
SHP465 MAS [75.0% (66/88)] than with placebo [30.2%
(26/86); both nominal p\ 0.001 based on the Cochran–
Mantel–Haenszel test].
3.4 Safety and Tolerability
3.4.1 Adverse Events
The frequency of TEAEs was higher with SHP465 MAS
than with placebo (Table 3). The most frequently reported
TEAEs (those reported by[5% of participants in either
SHP465 MAS treatment group) were decreased appetite,
dry mouth, insomnia, headache, anxiety, initial insomnia,
irritability, and bruxism. Most TEAEs were of mild-to-
moderate intensity; no serious TEAEs were reported.
Severe TEAEs were reported by two (2.2%) participants in
the placebo treatment group, one (1.1%) participant in the
12.5-mg/day SHP465 MAS treatment group, and five
(5.6%) participants in the 37.5-mg/day SHP465 MAS
treatment group (see Table 3 footnote for a complete list).
Treatment-emergent AEs leading to withdrawal of the
study drug were reported by seven (7.6%) and five (5.6%)
participants in the 12.5- and 37.50-mg/day SHP465 MAS
treatment groups, respectively (see Table 3 footnote for a
complete list).
3.4.2 Vital Signs
Mean ± SD changes in pulse, SBP, and DBP, respectively
were numerically greater with both SHP465 MAS treat-
ment groups (12.5 mg/day: 3.3 ± 10.52 bpm, 0.2 ± 7.24
and 1.0 ± 7.46 mmHg; 37.5 mg/day: 7.1 ± 11.48 bpm,
1.7 ± 9.99, and 2.8 ± 7.90 mmHg) compared with pla-
cebo (0.1 ± 8.35 bpm, -0.8 ± 9.99, and
0.1 ± 7.72 mmHg) at the final on-treatment assessment
(Table 3). Increases in blood pressure and pulse with
SHP465 MAS were greater with 37.5 mg/day of SHP465
MAS than with 12.5 mg/day of SHP465 MAS.
3.4.3 Other Safety and Tolerability Endpoints
At the final on-treatment assessment, mean ± SD weight
and BMI increases were observed with placebo
Fig. 3 Attention-Deficit/Hyperactivity Disorder Rating Scale with
Adult Prompts (ADHD-RS-AP) total score (a) and Clinical Global
Impressions-Improvement (CGI-I) score (b) by treatment week. MAS
mixed amphetamine salts, SD standard deviation; *p\ 0.001 for the
least-squares mean treatment difference vs. placebo for the change
from baseline in the ADHD-RS-AP total score at week 4 (based on
the mixed-effects model for repeated measures, including treatment,
visit, and the interaction of treatment with the visit as factors; with the
relevant baseline score as a covariate; and with an adjustment for the
interaction of the baseline score with the visit); p\ 0.001 for the
least-squares mean treatment difference vs. placebo for the CGI-I
score at week 4 (based on the mixed-effects model for repeated
measures, including treatment, visit, and the interaction of treatment
with the visit as factors; with the relevant baseline score as a
covariate; and with an adjustment for the interaction of the baseline
score with the visit)
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(0.30 ± 1.484 kg and 0.11 ± 0.510 kg/m2, respectively)
and mean decreases were observed with SHP465
MAS (12.5 mg/day: -0.97 ± 1.523 kg and -0.33 ±
0.519 kg/m2; 37.5 mg/day: -1.65 ± 2.333 kg and
-0.56 ± 0.777 kg/m2); changes in weight and BMI with
37.5 mg/day of SHP465 MAS were greater than those
with 12.5 mg/day of SHP465 MAS (Table 3). At the final
on-treatment assessment, mean ± SD changes in the
Fridericia-corrected QT interval were -1.7 ± 11.80 ms
with placebo, -3.0 ± 10.72 ms with 12.5 mg/day of
SHP465 MAS, and -1.6 ± 13.70 ms with 37.5 mg/day
of SHP465 MAS. No participant in any treatment group
experienced a Fridericia-corrected QT C500 ms or had a
change from baseline of C60 ms in Fridericia-corrected
QT.
During the baseline assessment, one participant in the
placebo group reported a lifetime history of a suicide
attempt on the C-SSRS. However, no participant in any
treatment group had a positive response for the on-study
assessments of the C-SSRS.
Table 2 Summary of efficacy endpoints, full analysis set
Placebo
(n = 86)
SHP465 MAS
12.5 mg/day
(n = 89)
37.5 mg/day
(n = 88)
ADHD-RS-AP total score (primary endpoint)
Mean ± SD change from baseline at wk 4 -11.0 ± 11.47 -18.1 ± 13.42 -23.8 ± 11.89
LS mean ± SEM change from baseline at wk 4 -10.4 ± 1.33 -18.5 ± 1.31 -23.8 ± 1.34
LS mean (95% CI) treatment difference vs. placebo for change from baseline
at wk 4a
-8.1 (-11.7, -4.4) -13.4 (-17.1, -9.7)
p value vs. placebob p\ 0.001 p\ 0.001
Effect sizec 0.67 1.11
CGI-I score (key secondary endpoint)
Mean ± SD score at wk 4 3.1 ± 1.05 2.4 ± 1.16 1.9 ± 1.10
LS mean ± SEM score at wk 4 3.1 ± 0.12 2.4 ± 0.12 1.9 ± 0.13
LS mean (95% CI) treatment difference vs. placebo for CGI-I at wk 4a -0.8 (-1.1, -0.4) -1.2 (-1.6, -0.9)
p value vs. placebob p\ 0.001 p\ 0.001
Effect sizec 0.68 1.11
ADHD-RS-AP inattentiveness subscale score
Mean ± SD change from baseline at wk 4 -6.1 ± 6.13 -10.3 ± 7.59 -13.8 ± 7.18
LS mean ± SEM change from baseline at wk 4 -5.7 ± 0.75 -10.4 ± 0.74 -13.8 ± 0.76
LS mean (95% CI) treatment difference vs. placebo for change from baseline
at wk 4a
-4.7 (-6.8, -2.6) -8.1 (-10.2, -6.0)
Nominal p value vs. placebob,d p\ 0.001 p\ 0.001
Effect sizec 0.70 1.19
ADHD-RS-AP hyperactivity/impulsivity subscale score
Mean ± SD change from baseline at wk 4 -4.9 ± 6.06 -7.8 ± 6.89 -9.9 ± 5.85
LS mean ± SEM change from baseline at wk 4 -4.7 ± 0.65 -8.0 ± 0.65 -10.0 ± 0.66
LS mean (95% CI) treatment difference vs. placebo for change from baseline
at wk 4a
-3.3 (-5.1, -1.5) -5.3 (-7.2, -3.5)
Nominal p value vs. placebob,d p\ 0.001 p\ 0.001
Effect sizec 0.56 0.91
ADHD-RS-AP Attention-Deficit/Hyperactivity Disorder Rating Scale with Adult Prompts, CGI-I Clinical Global Impressions-Improvement, CI
confidence interval, LS least squares, MAS mixed amphetamine salts, SD standard deviation, SEM standard error of the mean
Sample size at wk 4 (placebo, n = 77; 12.5 mg/day of SHP465 MAS, n = 78; 37.5 mg/day of SHP465 MAS, n = 73)
a SHP465 MAS—placebo (negative value indicates a treatment effect favoring SHP465 MAS)
b Based on the mixed-effects model for repeated measures, including treatment, visit, and the interaction of treatment with the visit as factors;
with the relevant baseline score as a covariate; and with an adjustment for the interaction of the baseline score with the visit
c Difference in the LS mean divided by the estimated SD from the unstructured covariance matrix
d Not included in the pre-specified fixed-sequence test procedure
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4 Discussion
In this study, SHP465 MAS (12.5 and 37.5 mg/day) exhib-
ited efficacy that was superior to placebo for reducing the
ADHD-RS-AP total score (the primary efficacy endpoint),
with a robust ES of 1.11 for 37.5 mg/day of SHP465 MAS.
The effect of 12.5 mg/day of SHP465MASwas numerically
lower than 37.5 mg/day of SHP465 MAS. The efficacy of
SHP465 MAS as measured by the primary efficacy assess-
ment was supported by the results of the key secondary
endpoint (CGI-I score reduction atweek 4) and other efficacy
endpoints (ADHD-RS-AP subscale score changes from
baseline at week 4 and dichotomized CGI-I improvement at
the final on-treatment assessment). These findings suggest
that SHP465 MAS, at 12.5 and 37.5 mg/day, is an effective
treatment in adults with ADHD.
The magnitude of the placebo-subtracted treatment
effects observed in this study (12.5 mg/day of SHP465
MAS, -8.1; 37.5 mg/day of SHP465 MAS, -13.4) is
within a range that is comparable to other studies of
SHP465 MAS in adults with ADHD [13, 15]. In a 7-week
dose-optimization (12.5–75 mg/day SHP465 MAS) study,
the LS mean treatment difference for the ADHD-RS-IV
total score reduction from baseline was -8.1 at the study
endpoint [13]. In a 6-week forced-dose study, the LS mean
treatment difference for ADHD-RS-IV total score reduc-
tions from baseline at the end of study ranged from -9.9
with 25 mg/day of SHP465 MAS (ES, 0.85) to -11.2 with
75 mg/day of SHP465 MAS (ES, 0.96) [15]. Although the
effects of SHP465 MAS in this study are generally aligned
with previous reports, the ES of 1.11 observed for
37.5 mg/day of SHP465 MAS exceeds that of previous
reports in adults [13, 15]. Although it cannot be stated that
dose-dependent treatment effects were observed in this
study (the SHP465 MAS doses used in the study were not
compared statistically), it is apparent that the placebo-
Table 3 Summary of
treatment-emergent adverse
events (TEAEs) and vital sign
changes, randomized safety
analysis set
Placebo (n = 89) SHP465 MAS
12.5 mg/day (n = 92) 37.5 mg/day (n = 90)
Any TEAE, n (%) 31 (34.8) 58 (63.0) 60 (66.7)
TEAEs related to study drug 19 (21.3) 50 (54.3) 54 (60.0)
Severe TEAEsa 2 (2.2) 1 (1.1) 5 (5.6)
TEAEs leading to discontinuationb 0 (0) 7 (7.6) 5 (5.6)
Serious TEAEs 0 (0) 0 (0) 0 (0)
TEAEs in[5% of participants in any treatment group, n (%)
Decreased appetite 4 (4.5) 18 (19.6) 27 (30.0)
Dry mouth 3 (3.4) 13 (14.1) 20 (22.2)
Insomnia 1 (1.1) 12 (13.0) 10 (11.1)
Headache 4 (4.5) 6 (6.5) 11 (12.2)
Anxiety 1 (1.1) 6 (6.5) 4 (4.4)
Initial insomnia 1 (1.1) 4 (4.3) 6 (6.7)
Irritability 0 (0) 5 (5.4) 3 (3.3)
Bruxism 0 (0) 1 (1.1) 5 (5.6)
Vital sign and weight change from baseline at final on-treatment assessment, mean ± SDc
Pulse, bpm 0.1 ± 8.35 3.3 ± 10.52 7.1 ± 11.48
Systolic blood pressure, mmHg -0.8 ± 9.99 0.2 ± 7.24 1.7 ± 9.99
Diastolic blood pressure, mmHg 0.1 ± 7.72 1.0 ± 7.46 2.8 ± 7.90
Weight, kg 0.30 ± 1.484 -0.97 ± 1.523 -1.65 ± 2.333
Body mass index, kg/m2 0.11 ± 0.510 -0.33 ± 0.519 -0.56 ± 0.777
MAS mixed amphetamine salts, SD standard deviation
a Severe TEAEs: dry mouth, muscle spasms, anxiety, auditory hallucination, initial insomnia, and
insomnia (37.5 mg/day of SHP465 MAS, n = 1 each); migraine (12.5 mg/day of SHP465 MAS, n = 1);
headache and laceration (placebo, n = 1 each)
b TEAEs leading to discontinuation: anxiety (12.5 mg/day of SHP465 MAS, n = 2; 37.5 mg/day of
SHP465 MAS, n = 2); depressed mood (12.5 mg/day of SHP465 MAS, n = 2); oral disorder, vomiting,
and headache (37.5 mg/day of SHP465 MAS, n = 1 each); fatigue, migraine, and insomnia (12.5 mg/day
of SHP465 MAS, n = 1 each)
c Sample size at final on-treatment assessment (placebo, n = 86; 12.5 mg/day of SHP465 MAS, n = 89;
37.5 mg/day of SHP465 MAS, n = 88)
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subtracted treatment difference and ES for 37.5 mg/day of
SHP465 MAS numerically exceeded those of 12.5 mg/day
of SHP465 MAS. This difference could be clinically
meaningful.
Although direct comparisons cannot be made between
agents across different studies, the magnitude of effect
observed in the current study is within a range observed for
other long-acting psychostimulants in adults with ADHD
[20, 21]. A 4-week fixed-dose study of lisdexamfetamine
dimesylate in adults with ADHD reported an ES range of
0.73 for lisdexamfetamine dimesylate 30 mg/day to 0.99
for lisdexamfetamine dimesylate 70 mg/day. In a 4-week
forced-dose study of MAS XR, the mean ES reported for
MAS XR (20–60 mg/day) was 0.80. In further support of
the robust ES observed in this study, a meta-analysis of
psychostimulant treatment effects on the ADHD-RS total
score from nine studies in adults with ADHD reported a
mean ES of 0.89 [22].
The short-term safety and tolerability of SHP465 MAS
in this study are consistent with observations from short-
term placebo-controlled studies of SHP465 MAS [13, 15]
and other long-acting psychostimulants in adults with
ADHD [20, 21, 23, 24]. The most frequently reported
TEAEs with SHP465 MAS (those occurring at a frequency
of[5% and at twice the rate of placebo) in this study—
decreased appetite, dry mouth, insomnia, headache, anxi-
ety, initial insomnia, irritability, and bruxism—were con-
sistent with those reported in other phase III studies of
SHP465 MAS in adults with ADHD [13, 15]. These
TEAEs have also been reported with other long-acting
psychostimulants [20, 21, 23, 24]. In previously published
short-term phase III studies, SHP465 MAS also increased
pulse (range: 0.9–5.4 bpm), SBP (range -0.3 to
1.5 mmHg), and DBP (range -0.3 to 1.8 mmHg), and
decreased weight (range -2.1 to –3.7 kg) [13, 15], which is
consistent with reports of other long-acting psychostimu-
lants [extended-release dexmethylphenidate (3.1–6.0 bpm;
SBP -0.5 mmHg; DBP 1.0 mmHg); lisdexamfetamine
(pulse 2.8–5.2 bpm; SBP 0.3–1.3 mmHg; DBP
0.8–1.6 mmHg); MAS XR (pulse 4.2–6.2 bpm; SBP
0.3–4.3 mmHg); osmotic controlled-release oral delivery
system methylphenidate (pulse 3.6 bpm; SBP
-1.2 mmHg; DBP 1.1 mmHg)] [20, 21, 23, 24].
The findings of this study should be considered in light
of potential limitations. Although SHP465 MAS was
titrated in the study, the forced-dose titration design used in
this study is not consistent with the flexible-dose treatment
strategies employed in clinical settings. As such, partici-
pants could have been maintained on doses that were
suboptimal in terms of maximizing the balance between
efficacy and safety/tolerability. Furthermore, a majority of
study participants [67.5% (183/271)] had an ADHD med-
ication treatment history, with the most frequently taken
medications being stimulants. Because it is beyond the
scope of this primary report to examine the role of treat-
ment history on response to SHP465 MAS, it is not known
how previous stimulant treatment would influence SHP465
MAS efficacy or tolerability.
Additionally, because the study was not powered for
the assessment of changes in ADHD-RS-AP subscale
scores or of dichotomized CGI-I improvement, the nom-
inal p-values reported for those endpoints should be
considered descriptive. It should also be noted that the
4-week duration of treatment was relatively short and
does not allow for assessment of the long-term safety and
tolerability of SHP465 MAS or of long-term clinical
outcomes regarding ADHD symptoms. In addition, the
current population was predominantly white and excluded
individuals with comorbid psychiatric disorders. As such,
generalizing these findings to a more diverse population
of adults with ADHD should be considered cautiously
because comorbidities are common in ADHD [25, 26] and
their effects on the efficacy, tolerability, and safety of
SHP465 MAS are not known. Last, the study also
excluded individuals who met BMI criteria for being very
severely obese (BMI C 40 kg/m2). Although the mean
BMI at baseline in this study indicates that on average
study participants met BMI criteria for being overweight
(BMI between 25 and 30 kg/m2), the exclusion of a
proportion of obese individuals could limit the general-
izability of these data because of the increased proportion
of adults diagnosed with ADHD who meet criteria for
obesity compared with adults who have not been diag-
nosed with ADHD [27].
5 Conclusions
The burden of illness of adult ADHD warrants efficacious
treatment options that address ADHD symptoms. In this
study, SHP465 MAS at a low dose of 12.5 mg/day was
effective compared with placebo in alleviating adult
ADHD symptoms. A dose of 37.5 mg/day of SHP465
MAS also demonstrated clinical efficacy, with an ES of
1.11. The safety profile of SHP465 MAS was consistent
with previous observations in studies of adult ADHD
treated with SHP465 MAS and other psychostimulants.
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